Although several GBA1 inhibitors have entered clinical trials for PD with or without GBA1 variants (Menozzi et al., 2023), our findings suggest that LRRK2 inhibitors already in clinical trials (Hu et al., 2023) could be tested in PD patients with (e.g., K198E) or without GBA1 variants. This evidence concerns the gene GBA1 and Parkinson disease.